en
Scientific article
Open access
English

Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland

Published inSwiss Medical Weekly, vol. 151, w20399
Publication date2021
Abstract

In the era of pangenotypic treatment regimens against hepatitis C virus (HCV) infection, data from postmarketing observational studies are crucial to better understand the treatment patterns used in specific countries and treatment outcomes under real-life conditions. We report data from Switzerland from an ongoing, multinational postmarketing observational study on the pangenotypic treatment regimen of glecaprevir (GLE; NS3/4A protease inhibitor) and pibrentasvir (PIB; NS5A inhibitor), coformulated as GLE/PIB.

Citation (ISO format)
MÜLLHAUPT, Beat et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. In: Swiss Medical Weekly, 2021, vol. 151, p. w20399. doi: 10.4414/smw.2021.20399
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1424-7860
157views
50downloads

Technical informations

Creation05/27/2021 3:54:00 PM
First validation05/27/2021 3:54:00 PM
Update time03/16/2023 12:40:04 AM
Status update03/16/2023 12:40:03 AM
Last indexation02/12/2024 1:26:52 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack